PNC Financial Services Group Inc. Purchases 1,280 Shares of argenex SE $ARGX

PNC Financial Services Group Inc. lifted its position in shares of argenex SE (NASDAQ:ARGX) by 65.8% in the fourth quarter, Holdings Channel reports. The institutional investor owned 3,226 shares of the company’s stock after acquiring an additional 1,280 shares during the period. PNC Financial Services Group Inc.’s holdings in argenex were worth $2,713,000 as of its most recent filing with the SEC.

Several other institutional investors have also made changes to their positions in ARGX. AQR Capital Management LLC increased its stake in argenex by 32.1% during the 1st quarter. AQR Capital Management LLC now owns 502 shares of the company’s stock worth $297,000 after acquiring an additional 122 shares during the period. NewEdge Advisors LLC lifted its position in argenex by 5,962.5% during the first quarter. NewEdge Advisors LLC now owns 1,455 shares of the company’s stock worth $862,000 after purchasing an additional 1,431 shares during the period. Focus Partners Wealth lifted its position in argenex by 22.3% during the first quarter. Focus Partners Wealth now owns 400 shares of the company’s stock worth $237,000 after purchasing an additional 73 shares during the period. Geneos Wealth Management Inc. grew its stake in argenex by 550.0% during the first quarter. Geneos Wealth Management Inc. now owns 117 shares of the company’s stock worth $69,000 after buying an additional 99 shares in the last quarter. Finally, Northwestern Mutual Wealth Management Co. grew its stake in argenex by 60.2% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 133 shares of the company’s stock worth $73,000 after buying an additional 50 shares in the last quarter. 60.32% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities analysts have recently commented on ARGX shares. Guggenheim boosted their target price on shares of argenex from $1,120.00 to $1,135.00 and gave the company a “buy” rating in a research report on Friday, May 8th. Oppenheimer cut their target price on argenex from $1,060.00 to $1,014.00 and set an “outperform” rating for the company in a research note on Thursday, April 2nd. Glj Research raised argenex to a “strong-buy” rating in a report on Friday, April 3rd. Zacks Research upgraded argenex from a “strong sell” rating to a “hold” rating in a research note on Friday, February 20th. Finally, Robert W. Baird boosted their price target on argenex from $858.00 to $867.00 and gave the stock a “neutral” rating in a report on Friday, February 27th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $1,017.78.

argenex Stock Up 0.2%

Shares of ARGX opened at $808.43 on Wednesday. The business has a 50-day simple moving average of $771.28 and a two-hundred day simple moving average of $815.45. argenex SE has a 12-month low of $510.05 and a 12-month high of $934.62. The stock has a market cap of $50.03 billion, a PE ratio of 35.99, a PEG ratio of 1.28 and a beta of 0.46.

argenex (NASDAQ:ARGX) last posted its earnings results on Tuesday, March 31st. The company reported $5.52 EPS for the quarter. argenex had a net margin of 31.31% and a return on equity of 33.28%. The business had revenue of $1.31 billion for the quarter. On average, equities research analysts expect that argenex SE will post 25.27 EPS for the current year.

argenex Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.